^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    M9466

    i
    Other names: M9466, HRS-1167, HRS1167, M 9466, HRS 1167, M-9466
    Associations

    News

    Trials
    Company:
    EMD Serono, Jiangsu Hengrui Pharma
    Drug class:
    PARP1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    21h
    A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone (clinicaltrials.gov)
    P1/2, N=66, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P1/2 trial
    |
    abiraterone acetate • prednisone • M9466
    30d
    M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (clinicaltrials.gov)
    P1, N=54, Recruiting, EMD Serono Research & Development Institute, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • M9466
    2ms
    A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    docetaxel • abiraterone acetate • prednisone • SHR-2554 • HRS-5041 • M9466
    3ms
    A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=100, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P1/2 trial • Metastases
    |
    docetaxel • abiraterone acetate • prednisone • SHR-2554 • HRS-5041 • M9466
    3ms
    M9466 as Single Agent or in Combination With Tuvusertib in Advanced Solid Tumors (DDRiver 501) (clinicaltrials.gov)
    P1, N=70, Recruiting, EMD Serono Research & Development Institute, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    tuvusertib (M1774) • M9466
    4ms
    Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab (clinicaltrials.gov)
    P2, N=130, Not yet recruiting, Fudan University
    New P2 trial • IO biomarker
    |
    BRCA (Breast cancer early onset)
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020) • M9466
    4ms
    M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (clinicaltrials.gov)
    P1, N=54, Not yet recruiting, EMD Serono Research & Development Institute, Inc.
    New P1 trial • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • M9466
    6ms
    M9466 as Single Agent or in Combination With Tuvusertib in Advanced Solid Tumors (DDRiver 501) (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, EMD Serono Research & Development Institute, Inc.
    New P1 trial • Combination therapy • Metastases
    |
    tuvusertib (M1774) • M9466
    7ms
    A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=54, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    Avastin (bevacizumab) • M9466
    8ms
    A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=54, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P1/2 trial • Combination therapy
    |
    Avastin (bevacizumab) • M9466
    9ms
    Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects (clinicaltrials.gov)
    P1, N=18, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    M9466 • rifampicin
    10ms
    Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    M9466 • rifampicin
    10ms
    Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P1 trial
    |
    M9466 • rifampicin
    2years
    Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=153, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HRD (Homologous Recombination Deficiency)
    |
    M9466
    over2years
    Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=153, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P1 trial
    |
    HRD (Homologous Recombination Deficiency)
    |
    M9466